MS-Perspektive - The Multiple Sclerosis Podcast copertina

MS-Perspektive - The Multiple Sclerosis Podcast

MS-Perspektive - The Multiple Sclerosis Podcast

Di: Nele von Horsten
Ascolta gratuitamente

Offerte di stagione | 0,99 €/mese per i primi 3 mesi

A seguire 9,99 €/mese – si applicano condizioni. Puoi disdire mensilmente.
In the MS-Perspektive Podcast, I present my view of multiple sclerosis and show you how you can make the best of the diagnosis. Because a beautiful and fulfilling life is also possible with multiple sclerosis. Here you will find information and strategies on how you can actively influence your course. In addition, I publish solo articles with my experiences, interview experts and on various topics related to living with MS as well as other affected people. In addition, there are a few episodes that serve the relaxation, positive attitude and stimulation.2023-2025 Igiene e vita sana
Episodi
  • #187: Aging in multiple sclerosis: relapses, progression and treatment choices with Dr. Yi Chao Foong

    #187: Aging in multiple sclerosis: relapses, progression and treatment choices with Dr. Yi Chao Foong
    Oct 14 2026

    Aging in multiple sclerosis brings new questions about relapses, gradual progression and treatment choices. In episode 187, Dr. Yi Chao Foong, an MS neurologist and researcher in Tasmania, explains why fewer relapses do not necessarily mean that MS has stopped changing.

    We discuss:

    • What changes in the aging immune system and what PIRA means.
    • Why late-onset MS needs careful diagnosis and individual treatment decisions.
    • Why stopping treatment can carry risks despite years of stability.
    • How rehabilitation, practical support and social connections can support independence.
    • What future biomarkers might add to treatment monitoring.

    Explore Dr. Foong's research and listen to episode 49 with Anthony Feinstein on CogeX. Further study links are included in the accompanying blog article.

    Links and resources

    • Read the interview and listen to episode 187 on the blog: https://ms-perspektive.de/en/187-aging-in-ms-yi-chao-foong/
    • Dr. Yi Chao Foong — MS Australia
    • Aging better with MS — research project
    • Late-onset MS treatment study
    • Ocrelizumab versus interferon/glatiramer acetate in people over 60
    • DISCOMS trial
    • DOT-MS trial
    • Clinically silent MRI lesions and treatment escalation
    • National Disability Insurance Scheme — Australia
    • Episode 049: CogeX study with Prof. Anthony Feinstein
    • English podcast archive

    Chapters

    00:00 Episode introduction
    00:45 Introducing Dr. Yi Chao Foong and aging in MS
    03:29 Why aging matters
    04:36 The aging immune system and PIRA
    06:56 Late-onset MS: diagnosis and treatment
    08:55 Higher-efficacy treatment in older people
    10:53 Stopping treatment: risks and uncertainties
    13:59 Why silent MRI lesions matter
    14:47 Personalizing treatment decisions
    16:30 Extended interval dosing and de-escalation
    18:00 Lifestyle, brain health and practical support
    19:52 Supporting independence
    22:39 Biomarkers and future monitoring
    24:38 Hopes for prevention research
    25:47 Takeaways for people with MS and families
    26:49 Following Dr. Foong's research
    27:37 Farewell

    ---

    See you soon and try to make the best out of your life,
    Nele

    For more information and positive thoughts, subscribe to my newsletter for free.

    Click here for an overview of all podcast episodes published so far.
    Mostra di più Mostra meno
    29 min
  • #186: Protecting nerve cells in multiple sclerosis: A new path toward neuroprotection with Prof. Manuel Friese

    #186: Protecting nerve cells in multiple sclerosis: A new path toward neuroprotection with Prof. Manuel Friese
    Oct 7 2026
    Why can multiple sclerosis progress even when relapses are well controlled? In episode 186, I speak with Prof. Manuel Friese about the next challenge in MS research: protecting nerve cells from damage and preserving function over time. Read the full interview on my blog: https://ms-perspektive.de/en/186-manuel-friese/ Manuel is a neurologist and clinician scientist who directs the Institute of Neuroimmunology and Multiple Sclerosis in Hamburg. His team's research explores why some nerve cells withstand inflammation while others degenerate. One unexpected finding was a protective role for complement factor H inside neurons, beyond its familiar role in regulating the immune system. We discuss how smoldering inflammation can keep nerve cells under stress, why oxidative damage matters and how ferroptosis, an iron-dependent form of cell death, fits into the picture. Manuel explains possible ways to strengthen the cells' own defenses and why getting a promising mechanism into a treatment remains a major challenge. We also talk about alpha-lipoic acid, the Octopus trial and the importance of careful clinical testing. Early research signals can be encouraging, but they do not yet prove that a treatment safely slows disability progression. Table of contents Opening & introductionUnderstanding neurodegeneration in MSThe new discovery: Complement factor HFrom discovery to potential therapyThe bigger picture: Protecting the brain in progressive MSLooking aheadClosing Introduction: Who is Prof. Manuel Friese? Prof. Manuel Friese: I'm a clinician scientist based in Hamburg, Germany, and I direct an institute for neuroimmunology and multiple sclerosis. The main focus of my research nowadays is to understand why progression in MS happens. That is also why we want to understand in much more depth how nerve cells react to inflammation. It is not so much about how inflammation occurs in the central nervous system. I think we have a fairly good understanding of that, but we still have not understood why neurons die. This extract has been edited for readability. Links and resources INIMS: follow the team's research Prof. Manuel Friese's UKE profileStudy: Intracellular complement factor H protects neurons during CNS inflammation, Nature, 2026Related paper: STING orchestrates the neuronal inflammatory stress response in multiple sclerosis Octopus interim results: alpha-lipoic acid moves to the next stage Octopus trial information Manuel Friese's research post on LinkedIn Related episodes #146: Chronic smoldering inflammation in MS with Dr. Klarissa Stürner#148: Recognizing silent progression in MS with Prof. Heinz Wiendl#050: The future of MS treatment with Prof. Tjalf Ziemssen Time stamps 00:32 Episode introduction00:45 Opening & introduction03:39 Understanding neurodegeneration in MS15:14 The new discovery: Complement factor H25:36 From discovery to potential therapy31:55 The bigger picture: Protecting the brain in progressive MS37:35 Looking ahead39:41 Closing41:11 Where to follow Manuel's research42:02 Next episode and farewell The contents are for information and do not replace individual medical advice. See you soon and try to make the best out of your life, Nele For more information and positive thoughts, subscribe to my newsletter for free. Click here for an overview of all podcast episodes published so far.
    Mostra di più Mostra meno
    44 min
  • #185: Living with MS in Mexico – who gets diagnosed, who gets treated, and who gets left behind?

    #185: Living with MS in Mexico – who gets diagnosed, who gets treated, and who gets left behind?
    Sep 30 2026

    An MS diagnosis can depend on where you live, whether you can reach a neurologist and how quickly you can get an MRI. In this episode, Nele speaks with neurologist and neuroimmunologist Dr. Enrique Gomez Figueroa about the gaps in MS care across Mexico. Enrique explains why official case numbers may miss people, what delays diagnosis and why access to an effective treatment can require a lengthy approval process. He also shares what research on switching therapies can tell us—and why listening to people with MS is essential.

    In this episode:

    • Why MS may be underdiagnosed in parts of Mexico
    • Barriers to diagnosis and distinguishing MS from NMOSD and MOGAD
    • Differences between treatments available on paper and in practice
    • When moving to a more effective therapy may be needed
    • How research, patient voices and advocacy can improve access
    Links and resources
    1. Read the full interview and blog post – https://ms-perspektive.de/185-ms-in-mexico/
    2. Atlas of MS: Mexico factsheet
    3. Enrique Gomez Figueroa's publications on PubMed
    4. Enrique Gomez Figueroa on LinkedIn
    5. MSBase study comparing treatment switches — einschließlich des Wechsels zu einer wirksameren Therapie
    6. MEXCTRIMS guideline: part I and part II
    7. 2024 revisions to the McDonald diagnostic criteria

    ---

    See you soon and try to make the best out of your life,
    Nele

    For more information and positive thoughts, subscribe to my newsletter for free.

    Click here for an overview of all podcast episodes published so far.
    Mostra di più Mostra meno
    36 min
adbl_web_anon_alc_button_suppression_t1
Ancora nessuna recensione